Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma

Clinical Endocrinology

Volumn 73, Issue 4, 2010, Pages 502-507

  Erem, Cihangir ^a   Kocak, Mustafa ^a   Nuhoglu, Irfan ^a   Yilmaz, Mustafa ^a   Ucuncu, Ozge ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHOLESTEROL; FIBRINOGEN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROLACTINOMA; PROTHROMBIN TIME; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE VOLUME;

EID: 77957048578     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03752.x     Document Type: Article

References (45)

1. Serri, O., Li, L., Mamputu, J.C. et al. (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clinical Endocrinology, 64 : 366 370.
2. Josimovich, J.B., Lavenhar, M.A., Devanesan, M.M. et al. (1987) Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertility and Sterility, 47 :785 791.
3. Prabhakar, V.K. Davis, J.R. (2008) Hyperprolactinaemia. Best Practice & Research. Clinical Obstetrics & Gynaecology, 22 : 341 353.
4. Aron, D.C., Findling, J.W. Tyrrell, J.B. (2007) Hypothalamus & pituitary gland. In :D.G. Gardner, D. Shoback eds. Greenspan's Basic & Clinical Endocrinology: A Lange Medical Book, 8th edn. The McGraw-Hill Companies, New York, 101 170.
5. Squizzato, A., Gerdes, V.E., Ageno, W. et al. (2007) The coagulation system in endocrine disorders: a narrative review. Internal and Emergency Medicine, 2 : 76 83.
6. Wallaschofski, H., Donné, M., Eigenthaler, M. et al. (2001) PRL as a novel potent cofactor for platelet aggregation. Journal of Clinical Endocrinology and Metabolism, 86 : 5912 5919.
7. Wallaschofski, H., Kobsar, A., Sokolova, O. et al. (2004) Differences in platelet activation by prolactin and leptin. Hormone and Metabolic Research, 36 : 453 457.
8. Wallaschofski, H., Kobsar, A., Sokolova, O. et al. (2004) Co-activation of platelets by prolactin or leptin - pathophysiological findings and clinical implications. Hormone and Metabolic Research, 36 : 1 6.
9. Raaz, D., Wallaschofski, H., Stumpf, C. et al. (2006) Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Hormone and Metabolic Research, 38 : 767 772.
10. Wallaschofski, H., Kobsar, A., Koksch, M. et al. (2003) Prolactin receptor signaling during platelet activation. Hormone and Metabolic Research, 35 : 228 235.
11. Rooth, E., Wallen, H., Antovic, A. et al. (2007) Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagulation and Fibrinolysis, 18 : 365 370.
12. Redlitz, A., Tan, A.K., Eaton, D.L. et al. (1995) Plasma carboxypeptidases as regulators of the plasminogen system. Journal of Clinical Investigation, 96 : 2534 2538.
13. van Tilburg, N.H., Rosendaal, F.R. Bertina, R.M. (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood, 95 : 2855 2859.
14. Eichinger, S., Schönauer, V., Weltermann, A. et al. (2004) Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood, 103 : 3773 3776. (Pubitemid 38596294)
15. Leebeek, F.W., Goor, M.P., Guimaraes, A.H. et al. (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. Journal of Thrombosis and Haemostasis, 3 : 2211 2218.
16. Montaner, J., Ribó, M., Monasterio, J. et al. (2003) Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke, 34 : 1038 1040.
17. Ravindranath, T.M., Goto, M., Iqbal, O. et al. (2007) Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clinical and Applied Thrombosis/Hemostasis, 13 : 362 368.
18. Broze Jr., G.J. (1992) The role of tissue factor pathway inhibitor in a revised coagulation cascade. Seminars in Hematology, 29 : 159 169.
19. Abumiya, T., Yamaguchi, T., Terasaki, T. et al. (1995) Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thrombosis and Haemostasis, 74 : 1050 1054.
20. Kobayashi, M., Wada, H., Wakita, Y. et al. (1995) Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 73 : 10 14.
21. Harris, G.M., Stendt, C.L., Vollenhoven, B.J. et al. (1999) Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. American Journal of Hematology, 60 : 175 180.
22. Yavuz, D., Deyneli, O., Akpinar, I. et al. (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. European Journal of Endocrinology, 149 : 187 193.
23. Sauro, M.D. Zorn, N.E. (1991) Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. Journal of Cellular Physiology, 148 : 133 138.
24. Girolami, A., Simioni, P., Scarano, L. et al. (1997) Venous and arterial thrombophilia. Haematologica, 82 : 96 100.
25. Atmaca, A., Gurlek, A., Dagdelen, S. et al. (2006) Hyperprolactinemia of pregnancy is not associated with increased in vivo platelet activity and shortened in vitro bleeding times. Experimental and Clinical Endocrinology and Diabetes, 114 : 188 191.
26. Landin-Wilhelmsen, K., Tengborn, L., Wilhelmsen, L. et al. (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clinical Endocrinology, 46 : 69 74.
27. Meade, T.W., Mellows, S., Brozovic, M. et al. (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, 2 : 533 537.
28. Wilhelmsen, L., Svärdsudd, K., Korsan-Bengtsen, K. et al. (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. New England Journal of Medicine 311 : 501 515.
29. Feinbloom, D. Bauer, K.A. (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arteriosclerosis, Thrombosis, and Vascular Biology, 25 : 2043 2053.
30. Quinsey, N.S., Greedy, A.L., Bottomley, S.P. et al. (2004) Antithrombin: in control of coagulation. International Journal of Biochemistry and Cell Biology, 36 : 386 389.
31. Roemisch, J., Gray, E., Hoffmann, J.N. et al. (2002) Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagulation and Fibrinolysis, 13 : 657 670.
32. Bayston, T.A. Lane, D.A. (1997) Antithrombin: molecular basis of deficiency. Thrombosis and Haemostasis, 78 : 339 343.
33. Cortellaro, M., Cofrancesco, E., Boschetti, C. et al. (1993) Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arteriosclerosis and Thrombosis, 13 : 1412 1417.
34. Hamsten, A., de Faire, U., Walldius, G. et al. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet, 2 : 3 9.
35. Merkle, C.J., Schuler, L.A., Schaeffer Jr., R.C. et al. (2000) Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor. Endocrine, 13 : 37 46.
36. Liu, Y.X., Liu, H.Z., Chen, Y.J. et al. (1998) Prolactin inhibition of FSH-induced tissue type plasminogen activator expression in cultured rat granulosa cells. Sheng Li Xue Bao, 50 : 11 18.
37. Maroney, S.A. Mast, A.E. (2008) Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfusion and Apheresis Science, 38 : 9 14.
38. Lwaleed, B.A. Bass, P.S. (2006) Tissue factor pathway inhibitor: structure, biology and involvement in disease. Journal of Pathology, 208 : 327 339.
39. Hoke, M., Kyrle, P.A., Minar, E. et al. (2005) Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thrombosis and Haemostasis, 94 : 787 790. (Pubitemid 41489238)
40. Monasterio, J., Bermúdez, P., Quiroga, D. et al. (2003/2004) Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study. Pathophysiology of Haemostasis and Thrombosis, 33 : 382 386.
41. Bajzar, L., Manuel, R. Nesheim, M.E. (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. Journal of Biological Chemistry, 270 : 14477 14484.
42. Pelkonen, R., Salmi, J. Lamberg, B.A. (1982) Interrelationship between TSH- and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis. Acta Endocrinologica, 100 : 184 188.
43. Heshmati, H.M., Turpin, G. de Gennes, J.L. (1987) Chronic hyperprolactinemia and plasma lipids in women. Klinische Wochenschrift, 65 : 516 519.
44. Oravec, S., Tomecková, E., Oravec, D. et al. (1985) Decreased apolipoprotein levels in women with hyperprolactinemia related to increased estradiol level: effect of hepatic lesion?. Endocrinologia Experimentalis, 19 : 312 316.
45. Fahy, U., Hopton, M.I., Hartog, M. et al. (1999) The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Human Reproduction, 14 : 285 287.